Skip to main content

Table 1 Baseline characteristics of the study population at CAISM/UNICAMP from 2000 to 2015

From: Adverse effects of antiretroviral therapy in pregnant women infected with HIV in Brazil from 2000 to 2015: a cohort study

Characteristics Median (%)
Age (years) 28 (13–46)
Parity 1 (0–9)
Schooling years (n = 769)
  < 8 60.9
 8–11 yrs. 32.2
  > 12 5.1
 No schooling 1.8
Ethnicity: White 61.2
HIV diagnosis (n = 789)
 Prior to pregnancy 62.5
 During pregnancy 37.5
In use of ART at conception (n = 787) 27.6
In use of Efavirenz at conception (n = 793) 10.2
Planned pregnancy (n = 382) 25.7
Heterosexual transmission (n = 408) 93.1
Baseline CD4 median (cells/mm3) 444 (3–1915)
Peripartum CD4 median (cells/mm3) 552 (5–2164)
Median time of ART use (days) 152.5 (4–292)
Median of detectable peripartum viral load (copies/ml) 815 (43–500.000)
Peripartum Viral Load < 50 (copies/ml) (n = 732) 58.9
CDC classification (n = 758)
 1 29.9
 2 51.6
 3 18.5
Substance abuse (n = 568) 14.3
Alcoholism (n = 528) 5.7
Smoking (n = 538) 14.1
ART adherence during prenatal care 84.3
Changed ART (n = 776) 19.2
Intravenous AZT (n = 775) 94.8
Antiretroviral regimens during pregnancy (n = 793)
 None 1.9
 AZT monotherapy 2.9
 Dual therapy 1.4
 2 NRTI + 1 NNRTI 17.9
  AZT + 3TC + NVP 16.8
  TDF + 3TC + NVP 0.1
  d4T + 3TC + NVP 0.5
  AZT + 3TC + EFV 0.3
  TDF + 3TC + EFV 0.3
 2 NRTI + 1 PI 74.9
  AZT + 3TC + LPV/r 48.5
  TDF + 3TC + LPV/r 3.4
  d4T + 3TC + LPV/r 0.1
  TDF + AZT + 3TC + LPV/r 1.5
  AZT + 3TC + ATV/r 1.8
  TDF + 3TC + ATV/r 1.0
  ABC + 3TC + ATV/r 0.1
  TDF + AZT + 3TC + ATV/r 0.3
  AZT + 3TC + NFV 16.8
  d4T + 3TC + NFV 0.1
  2 NRTI + Other PI* 1.3
 2 NRTI + PI** + RAL 0.9
 2 NRTI + NNRTI + PI 0.6
Total 100
  1. ART antiretroviral therapy, NRTI nucleos(t)ide reverse transcriptase inhibitors, AZT zidovudine, 3TC lamivudine, TDF tenofovir, d4T stavudine, ABC abacavir, NNRTI non-nucleoside reverse transcriptase inhibitor NVP nevirapine, EFV efavirenz, PI protease inhibitor, NFV nelfinavir, LPV lopinavir, r ritonavir, ATV atazanavir, IDV indinavir, FPV fosamprenavir, SQV saquinavir, RAL raltegravir, CDC Centers for Disease Control and Prevention
  2. Other PI* IDV/r (6), FPV/r (2), SQV (2)
  3. PI** DRV/r (3), LPV/r (4) included in LPV/r group
\